Iteos Therapeutics Inc
NASDAQ:ITOS
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.85
18.09
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Iteos Therapeutics Inc
Wall Street
Price Targets
ITOS Price Targets Summary
Iteos Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ITOS
is 35.19 USD
with a low forecast of 22.22 USD and a high forecast of 49.35 USD.
ITOS Last Price Targets
Iteos Therapeutics Inc
The latest public price target was made on Sep 16, 2024 by
Christopher Raymond
from
Raymond James
,
who expects
ITOS
stock to
rise by 336%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Christopher Raymond
Raymond James
|
36
USD
Upside 336% |
2 months ago
Sep 16, 2024
|
Piper Sandler Reiterates Overweight Rating on iTeos Therapeutics (ITOS)
StreetInsider
|
Eva Fortea Verdejo
Wells Fargo
|
31
USD
Upside 275% |
3 months ago
Aug 13, 2024
|
iTeos Therapeutics initiated with an Overweight at Wells Fargo
TheFly
|
|
Swayampakula Ramakanth
H.C. Wainwright
|
46
USD
Upside 457% |
6 months ago
May 13, 2024
|
iTeos Therapeutics price target raised to $46 from $44 at H.C. Wainwright
TheFly
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ITOS's stock price target?
Price Target
35.19
USD
According to Wall Street analysts, the average 1-year price target for
ITOS
is 35.19 USD
with a low forecast of 22.22 USD and a high forecast of 49.35 USD.
What is Iteos Therapeutics Inc's Revenue forecast?
Projected CAGR
31%
The
compound annual growth rate
of Iteos Therapeutics Inc's revenue for the next 3 years is
31%.
You don't have any saved screeners yet
